Antiphospholipid syndrome in childrenZajc Avramovič, Mojca (Avtor) Avčin, Tadej (Avtor) catastrophic antiphospholipid syndromechildreninfants antiphospholipid syndromesystemic lupus erythematosusantiphospholipid antibodiesthrombosisthrombocytopeniachorealupus anticoagulantsanticardiolipin antibodiesanti-β2 glycoprotein I antibodiesAntiphospholipid syndrome (APS) in children is a rare disease associated with significant morbidity and mortality. In comparison with APS in adults, pediatric APS has a more severe presentation with frequent recurrences of thrombotic events and a higher probability of life-threatening catastrophic APS. Nonthrombotic manifestations are also more common in the pediatric age group and can precede thrombosis. New classification criteria have been introduced recently and have not yet been assessed in pediatric patients with APS. In addition to anticoagulation drugs, other novel therapies have emerged including the use of B cell and complement inhibitors, especially in catastrophic APS. The purpose of this review is to provide a broad overview of aPL-related clinical manifestations in pediatric patients based on the analysis of published cohorts and data from the international pediatric APS registry. We also aim to illustrate APS in infants caused by transplacentally transferred maternal aPL, which is very rarely associated with acute thrombotic events in the perinatal period and more frequently with long-term neurodevelopmental abnormalities.20242024-09-25 08:29:06Članek v reviji162552UDK: 61ISSN pri članku: 1532-1770DOI: 10.1016/j.berh.2024.101986COBISS_ID: 204888323sl